🇪🇺 Exkivity in European Union

Exkivity (MOBOCERTINIB) regulatory status in European Union.

Marketing authorisation

EMA

  • Application: EMEA/H/C/005621
  • Marketing authorisation holder: Takeda Pharma A/S
  • Local brand name: Exkivity
  • Indication: Treatment of adult patients with epidermal growth factor receptor (EGFR) exon 20 insertion mutation-positive locally advanced or metastatic non-small cell lung cancer (NSCLC).
  • Status: withdrawn

Read official source →

Exkivity in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Oncology approved in European Union

Frequently asked questions

Is Exkivity approved in European Union?

Yes. EMA has authorised it.

Who is the marketing authorisation holder for Exkivity in European Union?

Takeda Pharma A/S holds the EU marketing authorisation.